{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:39:51Z","timestamp":1787020791855,"version":"build-2736575974"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100009392","name":"Prince Sattam bin Abdulaziz University","doi-asserted-by":"publisher","award":["PSAU\/2025\/R\/1446"],"award-info":[{"award-number":["PSAU\/2025\/R\/1446"]}],"id":[{"id":"10.13039\/100009392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002383","name":"King Saud University","doi-asserted-by":"publisher","award":["RSPD2025R1040"],"award-info":[{"award-number":["RSPD2025R1040"]}],"id":[{"id":"10.13039\/501100002383","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Chemistry"],"DOI":"10.1186\/s13065-025-01431-3","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T13:29:18Z","timestamp":1740749358000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Green stability-indicating RP-HPTLC approach for determining suvorexant in commercial tablet dosage forms"],"prefix":"10.1186","volume":"19","author":[{"given":"Prawez","family":"Alam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiyaz","family":"Shakeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed H.","family":"Alqarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed I.","family":"Foudah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tariq M.","family":"Aljarba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma M. Abdel","family":"Bar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohd","family":"Imran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,28]]},"reference":[{"key":"1431_CR1","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.ccc.2021.03.003","volume":"37","author":"K Azevedo","year":"2021","unstructured":"Azevedo K, Johnson M, Wassermann M, Evans-Wall J. Drugs of abuse-opioids, sedatives, hypnotics. Crit Care Clin. 2021;37:501\u201316.","journal-title":"Crit Care Clin"},{"key":"1431_CR2","doi-asserted-by":"publisher","first-page":"62","DOI":"10.2174\/2589977514666220914084543","volume":"15","author":"A Silva-Bessa","year":"2023","unstructured":"Silva-Bessa A, Forbes SL, Ferreira MT, Dinis-Oliveira RJ. Toxicological analysis of drugs in human mummified bodies and proposed guidelines. Curr Drug Res Rev. 2023;15:62\u201372.","journal-title":"Curr Drug Res Rev"},{"key":"1431_CR3","first-page":"264","volume":"39","author":"T Bennett","year":"2014","unstructured":"Bennett T, Bray D, Neville MW. Suvorexant, a dual orexin receptor antagonist for the management of insomnia. Pharm Ther. 2014;39:264\u20136.","journal-title":"Pharm Ther"},{"key":"1431_CR4","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1007\/s40265-014-0294-5","volume":"74","author":"LH Yang","year":"2014","unstructured":"Yang LH. Suvorexant: first global approval. Drugs. 2014;74:1817\u201322.","journal-title":"Drugs"},{"key":"1431_CR5","first-page":"26","volume":"1","author":"Z Ahmed","year":"2015","unstructured":"Ahmed Z, Ahmad A, Khan SA, Husain A. Pharmacological, pharmaceutical and safety profile of suvorexant: a dual orexin receptors antagonist for treatment of insomnia. Int Educ Sci Res J. 2015;1:26\u201330.","journal-title":"Int Educ Sci Res J"},{"key":"1431_CR6","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1177\/1060028015570467","volume":"49","author":"KV Patel","year":"2015","unstructured":"Patel KV, Aspesi AV, Evoy KE. Suvorexant: a dual orexin receptor antagonist for the treatment of sleep onset and sleep maintenance insomnia. Ann Pharmacother. 2015;49:477\u201383.","journal-title":"Ann Pharmacother"},{"key":"1431_CR7","first-page":"51243","volume":"79","author":"U.S. Drug Enforcement Administration","year":"2014","unstructured":"U.S. Drug Enforcement Administration. Schedules of controlled substances: placement of suvorexant into schedule IV. Final rule. Fed Reg. 2014;79:51243\u20137.","journal-title":"Fed Reg"},{"key":"1431_CR8","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1093\/jat\/bkx110","volume":"42","author":"B Waters","year":"2018","unstructured":"Waters B, Hara K, Ikematsu N, Takayama M, Matsusue A, Kashiwagi M, Kubo SI. Tissue distribution of suvorexant in three forensic autopsy cases. J Anal Toxicol. 2018;42:276\u201383.","journal-title":"J Anal Toxicol"},{"key":"1431_CR9","first-page":"425","volume":"6","author":"S Siddhartha","year":"2018","unstructured":"Siddhartha S, Ratna JV, Santosh T. Development and validation of HPLC method for the determination of suvorexant in pharmaceutical dosage forms. Int J Pharm Drug Anal. 2018;6:425\u201334.","journal-title":"Int J Pharm Drug Anal"},{"key":"1431_CR10","doi-asserted-by":"publisher","first-page":"23101","DOI":"10.1021\/acsomega.4c03976","volume":"9","author":"M Iqbal","year":"2024","unstructured":"Iqbal M, Haq N, Kalam MA, Imam F, Shakeel F. A simple, sensitive, and greener HPLC-DAD method for the simultaneous analysis of two novel orexin receptor antagonists. ACS Omega. 2024;9:23101\u201310.","journal-title":"ACS Omega"},{"key":"1431_CR11","first-page":"194","volume":"6","author":"S Siddhartha","year":"2019","unstructured":"Siddhartha S, Ratna JV, Tata SK. Development and validation of high performance liquid chromatographic method for the determination of suvorexant in rabbit plasma by HPLC-UV detection. J Emerg Technol Innov Res. 2019;6:194\u2013203.","journal-title":"J Emerg Technol Innov Res"},{"key":"1431_CR12","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1093\/jat\/bkz083","volume":"44","author":"B Skillman","year":"2020","unstructured":"Skillman B, Kerrigan S. Identification of suvorexant in blood using LC-MS-MS: important considerations for matrix effects and quantitative interferences in targeted assays. J Anal Toxicol. 2020;44:245\u201355.","journal-title":"J Anal Toxicol"},{"key":"1431_CR13","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1093\/jat\/bkaa109","volume":"45","author":"L Garcia","year":"2021","unstructured":"Garcia L, Tiscione NB, Yeatman DT, Richards-Waugh L. Novel and nonroutine benzodiazepines and suvorexant by LC-MS-MS. J Anal Toxicol. 2021;45:462\u201374.","journal-title":"J Anal Toxicol"},{"key":"1431_CR14","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jchromb.2018.05.006","volume":"1091","author":"B Skillman","year":"2018","unstructured":"Skillman B, Kerrigan S. Quantification of suvorexant in blood using liquid chromatography-quadrupole\/time of flight (LC-Q\/TOF) mass spectrometry. J Chromatogr B. 2018;1091:87\u201395.","journal-title":"J Chromatogr B"},{"key":"1431_CR15","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.jchromb.2015.07.056","volume":"1002","author":"SA Breidinger","year":"2015","unstructured":"Breidinger SA, Simpson RC, Mangin E, Woolf EJ. Determination of suvorexant in human plasma using 96-well liquid-liquid extraction and HPLC with tandem mass spectrometric detection. J Chromatogr B. 2015;1002:254\u20139.","journal-title":"J Chromatogr B"},{"key":"1431_CR16","first-page":"114","volume":"41","author":"M Iqbal","year":"2017","unstructured":"Iqbal M, Ezzeldin E, Khalil NY, Al-Rashood STA, Al-Rashood KA. Simple and highly sensitive UPLC-ESI-MS\/MS assay for rapid determination of suvorexant in plasma. J Anal Toxicol. 2017;41:114\u201320.","journal-title":"J Anal Toxicol"},{"key":"1431_CR17","first-page":"2185","volume":"36","author":"RA Xu","year":"2017","unstructured":"Xu RA, Chen KL, Jiao Y, Huo XL, Zhang Y. Quick method for the determination of suvorexant in plasma. Lat Am J Pharm. 2017;36:2185\u20139.","journal-title":"Lat Am J Pharm"},{"key":"1431_CR18","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1093\/jat\/bky078","volume":"43","author":"M Iqbal","year":"2019","unstructured":"Iqbal M, Khalil NY, Ezzeldin E, Al-Rashood KA. Simultaneous detection and quantification of three novel prescription drugs of abuse (suvorexant, Lorcaserin and brivaracetam) in human plasma by UPLC-MS-MS. J Anal Toxicol. 2019;43:203\u201311.","journal-title":"J Anal Toxicol"},{"key":"1431_CR19","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jchromb.2016.10.042","volume":"1040","author":"M Carson","year":"2017","unstructured":"Carson M, Kerrigan SJ. Quantification of suvorexant in urine using gas chromatography\/mass spectrometry. J Chromatogr B. 2017;1040:289\u201394.","journal-title":"J Chromatogr B"},{"key":"1431_CR20","first-page":"224","volume":"41","author":"S Sullinger","year":"2017","unstructured":"Sullinger S, Bryand K, Kerrigan S. Identification of suvorexant in urine using liquid chromatography-quadrupole\/time-of-flight mass spectrometry (LC-Q\/TOF-MS). J Anal Toxicol. 2017;41:224\u20139.","journal-title":"J Anal Toxicol"},{"key":"1431_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jpba.2018.10.005","volume":"164","author":"M Iqbal","year":"2019","unstructured":"Iqbal M, Ezzeldin E, Khalil NY, Alam P, Al-Rashood KA. UPLC-MS\/MS determination of suvorexant in urine by a simplified dispersive liquid-liquid micro-extraction followed by ultrasound assisted back extraction from solidified floating organic droplets. J Pharm Biomed Anal. 2019;164:1\u20138.","journal-title":"J Pharm Biomed Anal"},{"key":"1431_CR22","doi-asserted-by":"publisher","first-page":"39928","DOI":"10.1021\/acsomega.3c07123","volume":"8","author":"MH Alqarni","year":"2023","unstructured":"Alqarni MH, Iqbal M, Foudah AI, Aljarba TM, Bar FA, Alshehri S, Shakeel F, Alam P. Quantification of suvorexant in human urine using a validated HPTLC bioanalytical method. ACS Omega. 2023;8:39928\u201335.","journal-title":"ACS Omega"},{"key":"1431_CR23","doi-asserted-by":"publisher","first-page":"E105837","DOI":"10.1016\/j.arabjc.2024.105837","volume":"17","author":"TM Aljarba","year":"2024","unstructured":"Aljarba TM, Shakeel F, Alshehri S, Iqbal M, Foudah AI, Alqarni MH, Alhaiti A, Bar FMA, Alam P. Contrasting the validation parameters and greenness of normal-phase and reverse-phase stability-indicating HPTLC methods for lemborexant analysis. Arab J Chem. 2024;17:E105837.","journal-title":"Arab J Chem"},{"key":"1431_CR24","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.trac.2013.04.010","volume":"50","author":"A Galuszka","year":"2013","unstructured":"Galuszka A, Migaszewski Z, Namiesnik J. The 12 principles of green analytical chemistry and the significance mnemonic of green analytical practices. Trends Anal Chem. 2013;50:78\u201384.","journal-title":"Trends Anal Chem"},{"key":"1431_CR25","doi-asserted-by":"publisher","first-page":"E105582","DOI":"10.1016\/j.microc.2020.105582","volume":"159","author":"MM Abdelrahman","year":"2020","unstructured":"Abdelrahman MM, Abdelwahab NS, Hegazy MA, Fares MY, El-Sayed GM. Determination of the abused intravenously administered madness drops (tropicamide) by liquid chromatography in rat plasma; an application to Pharmacokinetic study and greenness profile assessment. Microchem J. 2020;159:E105582.","journal-title":"Microchem J"},{"key":"1431_CR26","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1039\/C9RA07825H","volume":"10","author":"P Alam","year":"2020","unstructured":"Alam P, Ezzeldin E, Iqbal M, Anwer MK, Mostafa GAE, Alqarni MH, Foudah AI, Shakeel F. Ecofriendly densitometric RP-HPTLC method for determination of Rivaroxaban in nanoparticle formulations using green solvents. RSC Adv. 2020;10:2133\u201340.","journal-title":"RSC Adv"},{"key":"1431_CR27","doi-asserted-by":"publisher","first-page":"E35","DOI":"10.1186\/s13065-023-00949-8","volume":"17","author":"HM Mohamed","year":"2023","unstructured":"Mohamed HM, Zaazaa HE, Abdelkawy M, Tantawy MA. Exploiting the power of UPLC in separation and simultaneous determination of Pholcodine, Guaiacol along with three specified Guaiacol impurities. BMC Chem. 2023;17:E35.","journal-title":"BMC Chem"},{"key":"1431_CR28","doi-asserted-by":"publisher","first-page":"E49","DOI":"10.1186\/s13065-023-00963-w","volume":"17","author":"MA Tantawy","year":"2023","unstructured":"Tantawy MA, Wahba IA, Saad SS, Ramadan NK. Classical versus chemometrics tools for spectrophotometric determination of Fluocinolone acetonide, Ciprofloxacin HCl and Ciprofloxacin impurity-A in their ternary mixture. BMC Chem. 2023;17:E49.","journal-title":"BMC Chem"},{"key":"1431_CR29","doi-asserted-by":"publisher","first-page":"E110307","DOI":"10.1016\/j.microc.2024.110307","volume":"200","author":"AR Ahmed","year":"2024","unstructured":"Ahmed AR, Galal SM, Ragab MAA, Karany MA. Tri-chromic sustainable tools of derivative\/discrete fourier transform HPLC convoluted peaks: application on LCZ696, an antihypertensive supramolecular complex, with its in process and degradation impurity analysis. Microchem J. 2024;200:E110307.","journal-title":"Microchem J"},{"key":"1431_CR30","doi-asserted-by":"publisher","first-page":"E100112","DOI":"10.1016\/j.greeac.2024.100112","volume":"9","author":"K Suthar","year":"2024","unstructured":"Suthar K, Desai S. A comparative greenness assessment of chromatographic methods for cilnidipine analysis and its combination. Green Anal Chem. 2024;9:E100112.","journal-title":"Green Anal Chem"},{"key":"1431_CR31","doi-asserted-by":"publisher","first-page":"A173","DOI":"10.1021\/es053241l","volume":"39","author":"LH Keith","year":"2005","unstructured":"Keith LH, Brass HJ, Sullivan DJ, Boiani JA, Alben KT. An introduction to the National environmental methods index. Env Sci Technol. 2005;39:A173\u20136.","journal-title":"Env Sci Technol"},{"key":"1431_CR32","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1039\/c0gc00667j","volume":"13","author":"Y Gaber","year":"2011","unstructured":"Gaber Y, Tornvall U, Kumar MA, Ali Amin M, Hatti-Kaul R. HPLC-EAT (Environmental assessment Tool): a tool for profiling safety, health and environmental impacts of liquid chromatography methods. Green Chem. 2011;13:2021\u20135.","journal-title":"Green Chem"},{"key":"1431_CR33","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1039\/c0gc00524j","volume":"13","author":"R Hartman","year":"2011","unstructured":"Hartman R, Helmy R, Al-Sayah M, Welch CJ. Analytical method volume intensity (AMVI): a green chemistry metric for HPLC methodology in the pharmaceutical industry. Green Chem. 2011;13:934\u20139.","journal-title":"Green Chem"},{"key":"1431_CR34","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.trac.2012.03.013","volume":"37","author":"A Galuszka","year":"2012","unstructured":"Galuszka A, Konieczka P, Migaszewski ZM, Namiesnik J. Analytical eco-scale for assessing the greenness of analytical procedures. Trends Anal Chem. 2012;37:61\u201372.","journal-title":"Trends Anal Chem"},{"key":"1431_CR35","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.talanta.2018.01.013","volume":"181","author":"J Plotka-Wasylka","year":"2018","unstructured":"Plotka-Wasylka J. A new tool for the evaluation of the analytical procedure: green analytical procedure index. Talanta. 2018;181:204\u20139.","journal-title":"Talanta"},{"key":"1431_CR36","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1039\/C8GC03875A","volume":"21","author":"MB Hicks","year":"2019","unstructured":"Hicks MB, Farrell W, Aurigemma C, Lehmann L, Weisel L, Nadeau K, Lee H, Moraff C, Wong M, Huang Y, Ferguson P. Making the move towards modernized greener separations: introduction of the analytical method greenness score (AMGS) calculator. Green Chem. 2019;21:1816\u201326.","journal-title":"Green Chem"},{"key":"1431_CR37","doi-asserted-by":"publisher","first-page":"10343","DOI":"10.1021\/acs.analchem.9b01872","volume":"91","author":"PM Nowak","year":"2019","unstructured":"Nowak PM, Koscielnaik P. What color is your method? Adaptation of the RGB additive color model to analytical method evaluation. Anal Chem. 2019;91:10343\u201352.","journal-title":"Anal Chem"},{"key":"1431_CR38","doi-asserted-by":"publisher","first-page":"E100056","DOI":"10.1016\/j.greeac.2023.100056","volume":"5","author":"PM Nowak","year":"2023","unstructured":"Nowak PM, Wietecha-Posluszny R, Plotka-Wasylka J, Tobiszewski M. How to evaluate methods used in chemical laboratories in terms of the total chemical risk? A ChlorTox scale. Green Anal Chem. 2023;5:E100056.","journal-title":"Green Anal Chem"},{"key":"1431_CR39","doi-asserted-by":"publisher","first-page":"10076","DOI":"10.1021\/acs.analchem.0c01887","volume":"92","author":"F Pena-Pereira","year":"2020","unstructured":"Pena-Pereira F, Wojnowski W, Tobiszewski W. AGREE-Analytical greenness metric approach and software. Anal Chem. 2020;92:10076\u201382.","journal-title":"Anal Chem"},{"key":"1431_CR40","unstructured":"International Conference on Harmonization (ICH), Q2 (R2). (2023) Guideline on validation of analytical procedures\u2013text and methodology, Geneva, Switzerland."},{"key":"1431_CR41","doi-asserted-by":"publisher","first-page":"E105960","DOI":"10.1016\/j.microc.2021.105960","volume":"164","author":"AI Foudah","year":"2021","unstructured":"Foudah AI, Shakeel F, Alqarni MH, Alam P. A rapid and sensitive stability-indicating green RP-HPTLC method for the quantitation of Flibanserin compared to green NP-HPTLC method: validation studies and greenness assessment. Microchem J. 2021;164:E105960.","journal-title":"Microchem J"},{"key":"1431_CR42","first-page":"256","volume":"2","author":"AA Bele","year":"2011","unstructured":"Bele AA, Khale A. An overview of thin layer chromatography. Int J Pharm Sci Res. 2011;2:256\u201367.","journal-title":"Int J Pharm Sci Res"},{"key":"1431_CR43","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1007\/s10337-013-2414-x","volume":"76","author":"I Malinowska","year":"2013","unstructured":"Malinowska I, Studzinski M, Neizabitowska K, Gadzikowska M. Comparison of TLC and different micro TLC techniques in analysis of tropane alkaloids and their derivatives mixture from Datura inoxia mill. Extract. Chromatographia. 2013;76:1327\u201332.","journal-title":"Chromatographia"},{"key":"1431_CR44","doi-asserted-by":"publisher","first-page":"E1305","DOI":"10.3390\/pr9081305","volume":"9","author":"P Alam","year":"2021","unstructured":"Alam P, Shakeel F, Alqarni MH, Foudah AI, Faiyazuddin M, Alshehri S. Rapid, sensitive, and sustainable reversed-phase HPTLC method in comparison to the normal-phase HPTLC for the determination of pterostilbene in capsule dosage form. Processes. 2021;9:E1305.","journal-title":"Processes"},{"key":"1431_CR45","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1556\/JPC.28.2015.1.12","volume":"28","author":"E El-Kimary","year":"2015","unstructured":"El-Kimary E, Ragab MAA. A validated high-performance thin-layer chromatographic method for the assay of two binary mixtures containing Omeprazole or its isomer Esomeprazole in pharmaceutical dosage forms. J Planar Chromatogr. 2015;28:74\u201382.","journal-title":"J Planar Chromatogr"},{"key":"1431_CR46","doi-asserted-by":"publisher","first-page":"E105693","DOI":"10.1016\/j.arabjc.2024.105693","volume":"17","author":"P Alam","year":"2024","unstructured":"Alam P, Shakeel F, Alshehri S, Alhaiti A, Alqarni MH, Foudah AI, Aljarba TM. Analysis of the greenness to determine Risperidone in commercial products using a green stability-indicating HPTLC method. Arab J Chem. 2024;17:E105693.","journal-title":"Arab J Chem"},{"key":"1431_CR47","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1093\/chromsci\/bmx081","volume":"56","author":"EI El-Kimary","year":"2018","unstructured":"El-Kimary EI, Khamis EF, Belal SF, Moneim MMA. Novel validated HPTLC method for the analysis of two binary mixtures containing Tamsulosin hydrochloride with antimuscarinic agents. J Chromatogr Sci. 2018;56:81\u201391.","journal-title":"J Chromatogr Sci"},{"key":"1431_CR48","doi-asserted-by":"publisher","first-page":"E105571","DOI":"10.1016\/j.arabjc.2023.105571","volume":"17","author":"F Shakeel","year":"2024","unstructured":"Shakeel F, Alam P, Alqarni MH, Iqbal M, Anwer MK, Alshehri S. A greener RP-HPTLC-densitometry method for the quantification of Apremilast in nanoformulations and commercial tablets: greenness assessment by analytical eco-scale, ChlorTox, and AGREE methods. Arab J Chem. 2024;17:E105571.","journal-title":"Arab J Chem"}],"container-title":["BMC Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13065-025-01431-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13065-025-01431-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13065-025-01431-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T13:31:16Z","timestamp":1740749476000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcchem.biomedcentral.com\/articles\/10.1186\/s13065-025-01431-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1431"],"URL":"https:\/\/doi.org\/10.1186\/s13065-025-01431-3","relation":{},"ISSN":["2661-801X"],"issn-type":[{"value":"2661-801X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,28]]},"assertion":[{"value":"26 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"54"}}